NEW YORK – A hectic year in the genomic research tools and molecular diagnostic industries was marked by efforts to develop diagnostic, surveillance, and research tools for the ongoing COVID-19 pandemic. But this wasn't the only subject of interest to our readers, as a look at the most-read articles on the GenomeWeb site for the year reveals strong interest in developments in the CRISPR field, initial public offerings among genomic tools developers, and Illumina's legal battles amid its efforts to complete the acquisition of Grail.
Below is a list of the 10 articles that gained the most interest among our readers in 2021.
- CDC to Withdraw EUA for COVID-19 Test; FDA Revokes Three Other EUAs for Non-Use, Agency Clearance
- CRISPR Researchers Engineer Highly Efficient Miniature Cas System
- Sema4 to Go Public Through Merger With Special Purpose Acquisition Company
- FTC Moves to Block Illumina's $8B Grail Acquisition
- Ancestry to Discontinue NGS-Based AncestryHealth Service
- Illumina Wins $8M Jury Verdict in BGI Patent Infringement Suit, Loses Patent
- Sequencing Startup Singular Genomics Files for $100M IPO
- FDA Issues Alert About Potential False Negative Test Results From SARS-CoV-2 Mutations
- Progenity to Close Genetics Lab as Focus Shifts to Therapeutics
- Global Supply Chain Issues Catch up to Illumina, Leading to Delayed NGS Projects